Peripheral B-cell dysregulation is associated with relapse after long-term quiescence in patients with multiple sclerosis.

ABSTRACT: B cells play a major role in multiple sclerosis (MS), with many successful therapeutics capable of removing them from circulation. One such therapy, alemtuzumab, is thought to reset the immune system without the need for ongoing therapy in a proportion of patients. The exact cells contributing to disease pathogenesis and quiescence remain to be identified. We utilized mass cytometry to analyze B cells from the blood of patients with relapse-remitting MS (RRMS) before and after alemtuzumab treatment, and during relapse. A complementary RRMS cohort was analyzed by single-cell RNA sequencing. The R package "Spectre" was used to analyze these data, incorporating FlowSOM clustering, sparse partial least squares-discriminant analysis and permutational multivariate analysis of variance. Immunoglo

SUBMITTER: Marsh-Wakefield F 

PROVIDER: S-EPMC9322415 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature